Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2021
BeiGene and Novartis expand their collaboration
BeiGene announced an agreement with Novartis to jointly develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe and Japan. The agreement also gives BeiGene rights to market and sell five approved Novartis oncology medicines in specified areas of China.
2021
BeiGene and WeDoctor sign strategic cooperation agreement
BeiGene and digital healthcare platform WeDoctor signed a strategic cooperation agreement to develop a cancer-focused health community and explore integrated services for cancer patients.
2021
BeiGene and Shoreline announce global cell-therapy collaboration
BeiGene and Shoreline Biosciences announced an exclusive global strategic collaboration to develop and commercialize a portfolio of NK-cell-based therapies for malignancies. BeiGene will lead global clinical development, while Shoreline will handle clinical manufacturing.
2021
China accepts SYLVANT marketing application for priority review
EUSA Pharma and BeiGene announced that China's National Medical Products Administration accepted the marketing application for SYLVANT (siltuximab for injection) and included it in priority review.
2021
BeiGene and Novartis announce tislelizumab collaboration
BeiGene and Novartis announced a collaboration and license agreement to develop and commercialize BeiGene's tislelizumab in specified markets. Novartis will handle regulatory submissions after a transition period and commercialization after regulatory approval in those licensed countries.
2021
Novartis signs tislelizumab in-licensing agreement with BeiGene
Novartis signed an agreement to in-license tislelizumab from BeiGene, securing development and commercialization rights in specified markets outside China. BeiGene retains rights in China and other countries; the transaction remains subject to the applicable waiting period.
2020
BeiGene and Assembly enter China collaboration for three HBV drug candidates
BeiGene and Assembly Biosciences announced a collaboration covering three clinical-stage hepatitis B core inhibitor candidates. Assembly granted BeiGene exclusive development and commercialization rights in China, including Hong Kong, Macao and Taiwan.
2020
BeiGene launches Xgeva commercially in China
BeiGene announced that Xgeva (denosumab injection) for giant cell tumor of bone had officially launched commercially in China.
2020
BeiGene appoints Angus Grant chief business executive
BeiGene appointed Angus Grant as chief business executive, responsible for business development, alliance management, external innovation and investment projects, and leading its global development strategy.
2020
Amgen completes purchase of BeiGene equity stake
Amgen completed its purchase of an approximately 20.5% equity stake in BeiGene for approximately $2.8 billion in cash.
2019
FDA approves Brukinsa for previously treated mantle cell lymphoma
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adults with previously treated mantle cell lymphoma.
2019
Amgen and BeiGene agree to co-develop oncology medicines globally
Under their announced collaboration, Amgen and BeiGene agreed to co-develop 20 Amgen oncology pipeline medicines globally and share development costs. BeiGene also agreed to commercialize three Amgen products in China under the cooperation agreement.
2019
Amgen announces purchase of a 20.5% stake in BeiGene
Amgen announced that it would purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash. The transaction had board approval and was expected to close in the first quarter of 2020, subject to stated conditions.